SCHEMBL12377818

SCHEMBL12377818

Cc1cccc(-c2noc(C(N)=O)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.56
NPC1 O15118 8/20 0.56
SMN1; SMN2 Q16637 7/20 0.56
HSD17B10 Q99714 3/20 0.56
TSHR P16473 3/20 0.56
KDM4E B2RXH2 2/20 0.56
GLA P06280 1/20 0.54
TP53 P04637 4/20 0.53
MAPT P10636 3/20 0.52
THRB P10828 1/20 0.52
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
POLB P06746 1/20 0.51
CASP3 P42574 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
LMNA P02545 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377814 0.83 GAA (0.54) RAB9ANPC1SMN1; SMN2HSD17B10TSHR
SCHEMBL12377816 0.83 TP53 (0.51) RAB9ANPC1SMN1; SMN2HSD17B10TSHR
SCHEMBL29959444 0.82 TP53 (0.54) RAB9ANPC1TP53GAA
SCHEMBL31323246 0.81 NPC1 (0.60) RAB9ANPC1SMN1; SMN2HSD17B10KDM4E
SCHEMBL12377812 0.80 MAPT (0.56) RAB9ANPC1TSHRMAPTTHRB
SCHEMBL1114407 0.76 S1PR1 (0.51) RAB9ANPC1SMN1; SMN2TP53MAPT
SCHEMBL2090313 0.76 L3MBTL1 (0.82) RAB9ANPC1SMN1; SMN2HSD17B10TSHR
SCHEMBL28706194 0.75 KCNT1 (0.49) RAB9ANPC1SMN1; SMN2HSD17B10TSHR
SCHEMBL28706195 0.75 KCNT1 (0.49) RAB9ANPC1SMN1; SMN2HSD17B10TSHR
SCHEMBL28710586 0.75 KCNT1 (0.49) RAB9ANPC1SMN1; SMN2HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D RAB9A 2645/4885NPC1 1132/4885SMN1; SMN2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.